AMED Research Program on Emerging and Re-emerging Infectious Disesses.
Study of antitoxins/antivenoms and their replacement by humanized monoclonal antibodies.[Ato Group]

For medical professionals For medical

Co-researcher Professor Emeritus Joe Chiba of the Tokyo University of Science explains serum therapy for novel coronavirus infections in Nikkei Biotech (Part 3).

Dr. Chiba’s article on plasma therapy was published in Nikkei Biotech.

Neutralizing Antibody Drugs Expected to Prevent and Treat New Coronas  

Treatment of New Coronas Moves from Plasma Therapy to Antibody Drugs (Part 2

https://bio.nikkeibp.co.jp/atcl/news/p1/20/09/29/07445/?n_cid=nbpbto_mled_am